SAN DIEGO, May 13, 2015 /PRNewswire/ — GenomeDx Biosciences today announced that multiple studies featuring clinical data from the company’s Decipher platform will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in the 2015 ASCO Annual Meeting Proceedings. Four of the abstracts feature validation data for the Decipher® Prostate Cancer Classifier, a genomic test for predicting cancer metastasis. One presentation features a genomic classifier developed from the Decipher platform for predicting treatment resistance in patients with bladder cancer.

Abstracts Accepted for Presentation in the 2015 ASCO Annual Meeting

Title: Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy
Presenter: Adam Dicker, M.D., Ph.D., Sidney Kimmel Cancer Center at Thomas Jefferson University
Abstract Number: 5016
Date/Time: May 30, 2015 | 4:45 PM6:00 PM
Location: Poster Discussion Session at S Hall A, E Arie Crown Theatre, Poster board #8

Title: p53-ness is associated with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin
Presenter: Roland Seiler, M.D., University of British Columbia
Abstract Number:  4512
Date/Time: June 1, 2015 | 4:45 PM6:00 PM
Location: Poster Discussion Session at S Hall A, E Arie Crown Theatre, Poster board #182

Title: Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort
Presenter: Ashley Ross, M.D., PhD, Johns Hopkins University
Abstract Number:  5059
Date/Time: May 30, 2015 | 1:15 PM4:45 PM
Location: S Hall A, Poster Board #53

Abstracts Accepted for Publication in the 2015 ASCO Annual Meeting Proceedings

Title: Evaluation of a Genomic Classifier in Primary Tumor and Lymph Node Metastases in Pre- and Post-Radical Prostatectomy Tissue Specimens from Patients with Lymph Node Positive Prostate Cancer
Abstract Number: e16087

Title: Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions
Abstract Number:  e16122

About Decipher®

The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.

Learn more at: www.DecipherTest.com and follow Decipher on Twitter at @DecipherTest and on Facebook.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at www.genomedx.com and follow us on Twitter at @GenomeDx, Facebook, LinkedIn and YouTube.

Media Contact:
Ian Stone
Canale Communications
619-849-5388
[email protected]

 

Source: PR Newswire Health